Skip to main content
. 2022 Aug 5;13(8):678. doi: 10.1038/s41419-022-05133-9

Fig. 2. NOTCH1 mutations in ACCx9 and ACCx11 PDX tumors show high levels of NOTCH1 signaling that is inhibited by AL101.

Fig. 2

A Tumor sections from four PDX models (ACCx9, ACCx11, ACCx5M1, and ACC6) collected at baseline (before implantation) were stained for NICD1, MYC, and Ki67 using an IHC. Representative images are shown. B Transactivation activity of wild-type full-length NOTCH1 (FL-NOTCH1), constitutively active γ-secretase dependent form of the NOTCH1 receptor (ΔECD-NOTCH1), and alleles containing mutations carried by ACCx9 and ACCx11 PDX tumors (ACC9-I1680N and ACC11-S1723ins28, respectively) was assessed using a dual-luciferase reporter assay. Bars represent the average of five independent experiments performed in triplicates and indicate fold-change relative to FL-NOTCH1 (red line). Percent inhibition induced by AL101 (gray bars) relative to DMSO (white bars) is indicated in blue. ***p < 0.001.